Table 2 Base case CUA of compared strategies in the first-line treatment of HR + / HER2- MBC
Comparison Ribociclib and Palbociclib with Letrozole | Comparison between Ribociclib and Palbociclib | ||||
|---|---|---|---|---|---|
Strategy | Letrozole | Palbociclib + Letrozole | Riboociclib + Letrozole | Riboociclib + Letrozole | Palbociclib + Letrozole |
Cost ($) | 7,531.34 | 82,041.04 | 96,247.45 | 96,247.45 | 82,041.04 |
QALYs | 2.861 | 3.403 | 3.597 | 3.597 | 3.403 |
Incremental Cost($) | 74,509.7 | 88,716.11 | 14,206.41 | ||
Incremental QALYs | 0.542 | 0.736 | 0.194 | ||
ICER($/QALY) | (undefined) | 137,302 | 120,478 | 73,342 | |
NPV($) | 5,528.21 | -66,504.15 | -79,826.29 | -79,826.29 | -66,504.15 |